Cargando…

Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH)

Systemic sclerosis (SSc) is a rare autoimmune disorder with multi-organ involvement. SSc-associated pulmonary arterial hypertension (SSc-PAH) is one of the leading causes of morbidity and mortality in the SSc population. With advances in our understanding of pulmonary arterial hypertension (PAH) dia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Argula, Rahul G, Ward, Celine, Feghali-Bostwick, Carol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916691/ https://www.ncbi.nlm.nih.gov/pubmed/31853179 http://dx.doi.org/10.2147/TCRM.S219024

Ejemplares similares

Genetics of systemic sclerosis: recent advances
por: Ramos, Paula S., et al.
Publicado: (2015)

First Characterization of the Transcriptome of Lung Fibroblasts of SSc Patients and Healthy Donors of African Ancestry
por: Renaud, Ludivine, et al.
Publicado: (2023)

Estradiol levels are elevated in older men with diffuse cutaneous SSc and are associated with decreased survival
por: Baker Frost, DeAnna, et al.
Publicado: (2019)

3420 Estradiol levels are elevated in older men with diffuse cutaneous SSc and are associated with decreased survival
por: Baker Frost, DeAnna, et al.
Publicado: (2019)

Symptom phenotypes in pulmonary arterial hypertension: The PAH “symptome”
por: Matura, Lea Ann, et al.
Publicado: (2022)

Impact of Three Different Algorithms for the Screening of SSc-PAH and Comparison with the Decisions of a Multidisciplinary Team
por: Coirier, Valentin, et al.
Publicado: (2021)

The Molecular Mechanisms of Systemic Sclerosis-Associated Lung Fibrosis
por: Mouawad, Joe E., et al.
Publicado: (2023)

382 The Role of the IL-6-IGF-II Axis in Systemic Sclerosis-Associated Lung Fibrosis
por: Adewale, Adegboyega Timothy, et al.
Publicado: (2023)

Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
por: Steele, Peter, et al.
Publicado: (2010)

The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients
por: Sikirica, Mirko, et al.
Publicado: (2014)

Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
por: Calcaianu, George, et al.
Publicado: (2017)

Pulmonary-arterial-hypertension (PAH)-on-a-chip: fabrication, validation and application
por: Al-Hilal, Taslim A., et al.
Publicado: (2020)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Optimization of a murine and human tissue model to recapitulate dermal and pulmonary features of systemic sclerosis
por: Watanabe, Tomoya, et al.
Publicado: (2017)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

The Membrane-Associated Adaptor Protein DOK5 Is Upregulated in Systemic Sclerosis and Associated with IGFBP-5-Induced Fibrosis
por: Yasuoka, Hidekata, et al.
Publicado: (2014)

Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH
por: McCollister, Deborah, et al.
Publicado: (2016)

COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City
por: Sulica, Roxana, et al.
Publicado: (2021)

Sickle Cell Disease (SCD) Leading to Pulmonary Arterial Hypertension (PAH) and Cholelithiasis (CL)
por: Chacko, Saran, et al.
Publicado: (2023)

Insulin-Like Growth Factor Binding Proteins-3 and -5: Central Mediators of Fibrosis and Promising New Therapeutic Targets
por: Veraldi, Kristen L, et al.
Publicado: (2012)

The exercise in pulmonary arterial hypertension (ExPAH) study: A randomized controlled pilot of exercise training and multidisciplinary rehabilitation in pulmonary arterial hypertension
por: Chia, Karen S. W., et al.
Publicado: (2022)

Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)
por: Preston, Ioana R., et al.
Publicado: (2015)

Identification of Impacted Pathways and Transcriptomic Markers as Potential Mediators of Pulmonary Fibrosis in Transgenic Mice Expressing Human IGFBP5
por: Nguyen, Xinh-Xinh, et al.
Publicado: (2021)

Usefulness of Red Cell Width Distribution (RDW) in the Assessment of Children with Pulmonary Arterial Hypertension (PAH)
por: Zuk, Malgorzata, et al.
Publicado: (2019)

Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment
por: Saygin, Didem, et al.
Publicado: (2019)

The Challenge to Decide between Pulmonary Hypertension Due to Chronic Lung Disease and PAH with Chronic Lung Disease
por: Olschewski, Horst
Publicado: (2021)

Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin
por: Idrees, Majdy, et al.
Publicado: (2015)

Acute Deterioration of Pulmonary Arterial Hypertension (PAH) in a Patient with Neurofibromatosis Type 1 (NF1)
por: Tanaka, Seiya, et al.
Publicado: (2019)

Risk assessment in systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study
por: Wang, Qian, et al.
Publicado: (2022)

Pulmonary Arterial Hypertension (PAH) as the Initial Manifestation of Systematic Lupus Erythematosus (SLE): A Rare Presentation
por: Kamath, Sangita D, et al.
Publicado: (2023)

Which Functional Classification Scale is Optimal for Children with Pulmonary Hypertension (PAH)?
por: Migdał, Anna, et al.
Publicado: (2020)

Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature
por: Lande, Roberto, et al.
Publicado: (2020)

Epigenetics of hypoxic pulmonary arterial hypertension following intrauterine growth retardation rat: epigenetics in PAH following IUGR
por: Xu, Xue-Feng, et al.
Publicado: (2013)

Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document
por: Rahaghi, Franck F., et al.
Publicado: (2017)

Statin treatment prevents the development of pulmonary arterial hypertension in a nonhuman primate model of HIV-associated PAH
por: Rabacal, Whitney, et al.
Publicado: (2019)

Activation of renin–angiotensin–aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats
por: Yuan, Yi-Ming, et al.
Publicado: (2015)

Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD)
por: Tsang, Yuen, et al.
Publicado: (2023)

A prognostic model for systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study
por: Qu, Jingge, et al.
Publicado: (2023)

Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis
por: Artlett, Carol M., et al.
Publicado: (2017)

Evaluating the role of serum uric acid in the risk stratification and therapeutic response of patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD)
por: Luo, Jun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_auubufq0o24q30nqnnedv17s8h